Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Change in receivables

Change in receivables at other companies

Eli Lilly logo
Eli LillyLLY
$1.75B+225%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$7.72M+103%
LQD
Liquidia CorporationLQDA
$20.06M+1,463%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's change in receivables?
MoonLake Immunotherapeutics (MLTX) reported change in receivables of $894K in Q1 2026.
How has MoonLake Immunotherapeutics's change in receivables changed year-over-year?
MoonLake Immunotherapeutics's change in receivables increased by 512.3% year-over-year, from $146K to $894K.
What is the long-term trend for MoonLake Immunotherapeutics's change in receivables?
Over 2 years (2023 to 2025), MoonLake Immunotherapeutics's change in receivables has grown at a 55.3% compound annual growth rate (CAGR), from $840K to $2.03M.
What does change in receivables mean?
Change in total receivables including trade and non-trade receivables.